Recombinant Dna Technique Included In Method Of Making A Protein Or Polypeptide Patents (Class 435/69.1)
  • Patent number: 11999770
    Abstract: The present invention relates to peptides, methods for production of the same, nanoparticle formulations of the same and the use of these new peptides and nanoparticle formulations as inhibitors of protein-protein interactions, in particular for application in the treatment of diseases associated with overexpression of the RAN gene.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: June 4, 2024
    Assignee: UNIVERSITY OF BRADFORD
    Inventors: Mohamed El-Tanani, Paul McCarron, Ahmed Faheem
  • Patent number: 11965189
    Abstract: The present invention relates to cellobiohydrolase variants having increased thermal activity or thermostability, polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants.
    Type: Grant
    Filed: March 24, 2017
    Date of Patent: April 23, 2024
    Assignee: Novozymes A/S
    Inventors: Mark Wogulis, Leslie DeMars, David Osborn
  • Patent number: 11950924
    Abstract: Embodiments of the present systems and methods may relate to a non-invasive system with diagnostic and treatment capacities that use a unified code that is intrinsic to physiological brain function. For example, in an embodiment, a computer-implemented method for affecting living neural tissue may comprise receiving at least one signal from at least one read modality, the signal representing release of photons from mitochondria of the living neural tissue, computing at least one signal to effect alterations to the living neural tissue based on the received input signal, the computed signal adapted to cause transmission of photons to the living neural tissue, and delivering the photons to the living neural tissue to effect alterations to the living tissue.
    Type: Grant
    Filed: April 13, 2020
    Date of Patent: April 9, 2024
    Inventor: Newton Howard
  • Patent number: 11938193
    Abstract: The present disclosure provides compositions comprising chemerin and the methods of use thereof. The compositions of the disclosure are useful in the treatment of cancer.
    Type: Grant
    Filed: January 9, 2017
    Date of Patent: March 26, 2024
    Assignee: Washington University
    Inventors: Russell Pachynski, Holbrook Kohrt, Jason Yonehiro, Brian Zabel
  • Patent number: 11919938
    Abstract: Fusion proteins comprising an extracellular domain of PD1 (programmed cell death protein-1) protein and/or an extracellular domain of PD-L1 (programmed cell death-ligand 1 protein (CD274 or B7-H1)) protein. Portions of the extracellular domains are expressed in specific configurations and purified as protein and used in immunoassays to monitor the circulating levels of biotherapeutic antibodies to these proteins. Also described is a method of determining the amount of circulating levels of a biotherapeutic antibody in a biological sample obtained from a patient, wherein a patient has undergone at least one dose of immunotherapy.
    Type: Grant
    Filed: November 29, 2018
    Date of Patent: March 5, 2024
    Assignee: GRIFOLS DIAGNOSTIC SOLUTIONS INC.
    Inventors: Jody Berry, Elizabeth Antony Booth, Joyee Antony George, Elisabete Nascimento, Daniel Nagore Casas
  • Patent number: 11913033
    Abstract: The present invention is directed to nucleic acid molecules which encode novel luciferases, functional fragments thereof, homologs and mutants, as well as to proteins encoded by said nucleic acids. The nucleic acid molecules of interest are isolated from fungi or obtained by genetic engineering methods. Also, host cells, stable cell lines and transgenic organisms comprising said nucleic acid molecules are provided. In addition, antibodies specific to the proteins of the present invention are provided. Said proteins and nucleic acids are used in many applications and methods, in particular, in labelling organisms, cells, cellular organelles, or proteins. Also, said protein and nucleotide compositions are used in methods for detecting protein-protein interactions, for testing promoter activity under various conditions. Finally, provided are kits for the use of proteins and nucleic acids of the present invention in the diversity of methods and applications.
    Type: Grant
    Filed: December 6, 2017
    Date of Patent: February 27, 2024
    Assignee: Light Bio, Inc.
    Inventor: Il'ya Viktorovich Yampol'skiy
  • Patent number: 11898154
    Abstract: Disclosed are constructs and methods for expressing DNAs of interest in particular in non-primate eukaryotic host cells that display advantages with regard quantity and quality of expression including high stability of expression and, if appropriate, transport of the expression product out of the cell.
    Type: Grant
    Filed: February 1, 2014
    Date of Patent: February 13, 2024
    Assignee: SELEXIS S.A.
    Inventors: Valerie Le Fourn, Nicolas Mermod, Alexandre Regamey, Montse Buceta, Deborah Ley, Niamh Harraghy, Kaja Kostyrko, Pierre-Alain Giro, David Calabrese
  • Patent number: 11890327
    Abstract: The invention pertains to a recombinant polypeptide comprising a truncated von Willebrand Factor (VWF) for use in the treatment or prophylaxis of a blood coagulation disorder, said treatment or prophylaxis comprising administering the recombinant polypeptide and a Factor VIII protein (FVIII) extravascular to a subject having a blood coagulation disorder, wherein said recombinant polypeptide is capable of binding to said FVIII, and wherein the molar ratio of the recombinant polypeptide to be administered to the FVIII to be administered is higher than 50.
    Type: Grant
    Filed: November 10, 2017
    Date of Patent: February 6, 2024
    Assignee: CSL Behring Lengnau AG
    Inventors: Sabine Pestel, Elmar Raquet, Thomas Weimer
  • Patent number: 11890108
    Abstract: In embodiments, devices, methods and systems to analyze the different mediums of brain function in a mathematically uniform manner may be provided. These devices, methods and systems may manifest at several levels and ways relating to brain physiology, including neuronal activity, molecular chirality and frequency oscillations. For example, in an embodiment, a computer-implemented method for determining structure of living neural tissue may comprise receiving at least one signal from at least one read modality, the signal representing at least one physical condition of the living neural tissue, determining action potentials based on the signals received from the read modalities, determining frequency oscillations based on the signals received from the read modalities and the action potentials, and determining neuron network structures based on the signals received from the read modalities, the action potentials, and the frequency oscillations.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: February 6, 2024
    Inventor: Newton Howard
  • Patent number: 11884719
    Abstract: The present invention provides binding proteins, such as antibodies and antigen-binding fragments, which specifically bind to human IL-36 cytokines, IL-36?, IL-36?, and/or IL-36?, and block the IL-36 stimulated signaling pathways. Compositions comprising such binding proteins and methods of making and using such binding proteins are also provided.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: January 30, 2024
    Assignee: 23andMe, Inc.
    Inventors: Chingwei Vivian Lee, Germaine Fuh-Kelly, Louise Scharf, Tina Thai, Ashka Bharat Patel, Shashank Bharill, Erik Edward Karrer
  • Patent number: 11859216
    Abstract: Bacillus agaradhaerens strain WDG185 expresses an inulosucrase that efficiently synthesizes a broad range of IOS with a GF range of GF3-GF30. The isolated and/or purified inulosucrase, recombinantly engineered variants thereof, active fragments thereof, synthetic nucleic acids encoding the inulosucrase, its variants, or its active fragments, host cells comprising the synthetic nucleic acids, and compositions comprising the inulosucrase are provided. Methods of using the compositions include the manufacture of inulooligosaccharides.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: January 2, 2024
    Assignee: Danisco US Inc.
    Inventors: Slavko Kralj, Marc Kolkman, Chris Leeflang, Johannes G. De Nobel, Arjen Hoekstra, Veli Alkan
  • Patent number: 11814409
    Abstract: Herein is reported the use of an immobilized non-covalent complex of a neonatal Fc receptor (FcRn) and beta-2-microglobulin (b2m) as affinity chromatography ligand in general and, for example, for the determination of the in vivo half-live of an antibody by determining the ratio of the retention times of the antibody and a reference antibody.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: November 14, 2023
    Inventors: Roberto Falkenstein, Hubert Hertenberger, Petra Rueger, Tilman Schlothauer
  • Patent number: 11788109
    Abstract: A microorganism useful as an expression host for ?-Glu-Val synthetase and a method for producing ?-Glu-Val-Gly using ?-Glu-Val synthetase expressed in the microorganism are provided. By using ?-Glu-Val synthetase expressed in a bacterium, such as Escherichia bacteria, modified so that the activity of a protein encoded by a ybdK gene (YBDIQ is reduced as an expression host, ?-Glu-Val-Gly is produced (Yom Glu, Val, and Gly as raw materials.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: October 17, 2023
    Assignee: AJINOMOTO CO., INC.
    Inventors: Ayako Sasahara, Takayuki Ito, Hiroyuki Nozaki
  • Patent number: 11787876
    Abstract: The present disclosure relates, in general, human antibodies against human parathyroid hormone receptor 1 (PTH1R) and methods of use of such antibodies in the treatment of cancer, Humoral Hypercalcemia of Malignancy (HHM), or Primary Hyperparathyroidism (PHPT) and Secondary Hyperparathyroidism (SHPT) and cachexia.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: October 17, 2023
    Assignee: XOMA (US) LLC
    Inventors: Raphael D. Levy, Hassan Issafras, Agnes Choppin Holmes, Kirk W. Johnson, Amer M. Mirza, Daniel H. Bedinger, Rachel A. Hunt, Toshihiko Takeuchi, Kiranjit Kaur Ahluwalia, Robyn Cotter
  • Patent number: 11767362
    Abstract: The invention provides compositions and methods for treating cancers. The methods comprising administering a PD-1 axis binding antagonist and an anti-GPC3 antibody. The compositions comprising a pharmaceutical composition for treating cancer which comprises a PD-1 axis binding antagonist and an anti-GPC3 antibody. Also disclosed are a pharmaceutical composition to be used in combination with a PD-1 axis binding antagonist for treating cancer which comprises an anti-GPC3 antibody as the active ingredient; and a pharmaceutical composition to be used in combination with an anti-GPC3 antibody for treating cancer which comprises as the active ingredient a PD-1 axis binding antagonist.
    Type: Grant
    Filed: March 14, 2017
    Date of Patent: September 26, 2023
    Assignees: Chugai Seiyaku Kabushiki Kaisha, Genentech, Inc.
    Inventors: Mika Endo, Atsuhiko Kato, Toshihiko Ohtomo, Kenji Adachi, Yasuko Kinoshita, Yoshinori Narita
  • Patent number: 11752225
    Abstract: The present disclosure provides novel processes for providing sterile, pre-filled syringes or injection devices for pharmaceutical compositions, including protein and biopharmaceutical formulations. In some examples, secondary packaging is performed in an aseptic environment, which removes the need for any terminal sterilization method. In some examples, the aseptic packaging method results in a sterile injection device suitable for use in ophthalmic injections.
    Type: Grant
    Filed: May 21, 2021
    Date of Patent: September 12, 2023
    Assignee: Coherus BioSciences, Inc.
    Inventors: Wendy Shieu, Gerald Llorach
  • Patent number: 11718844
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: August 8, 2023
    Assignee: BIOATLA, INC.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11718849
    Abstract: The present invention relates to libraries of phosphopeptide-encoding oligonucleotides and methods of preparing such libraries. The present invention also relates to methods of detecting, visualizing, or screening for phosphorylation-dependent protein-protein interactions using recombinant phosphopeptides and/or phosphopeptide-encoding oligonucleotides. The present invention also relates to sets or kits of oligonucleotides having regions that encode phosphopeptides.
    Type: Grant
    Filed: February 18, 2019
    Date of Patent: August 8, 2023
    Assignee: AGILENT TECHNOLOGIES, INC.
    Inventors: Jesse Rinehart, Karl Barber, Farren Isaacs, Jeffrey R Sampson
  • Patent number: 11702628
    Abstract: The invention relates to a method of culturing mammalian cells expressing a heterologous protein in a perfusion cell culture comprising increasing the potassium concentration and decreasing the molar ratio of sodium to potassium to reduce wasteful cell bleed and to increase protein production. The invention further relates to a serum-free perfusion medium comprising a high potassium ion concentration and a low molar ratio of sodium to potassium and to the use of this medium for use in culturing cells in a perfusion culture during production phase or for reducing the cell bleed volume during production phase.
    Type: Grant
    Filed: March 27, 2018
    Date of Patent: July 18, 2023
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Samantha Wang, Henry Lin
  • Patent number: 11685940
    Abstract: Provided is a method capable of replicating or amplifying circular DNA, and particularly, long-chain circular DNA, in a cell-free system. Specifically, provided is a method for suppressing generation of a DNA multimer as a by-product, when circular DNA having a replication origin sequence (origin of chromosome (oriC)) is replicated or amplified by using the following enzyme groups: (1) a first enzyme group that catalyzes replication of circular DNA; (2) a second enzyme group that catalyzes an Okazaki fragment maturation and synthesizes two sister circular DNAs constituting a catenane; and (3) a third enzyme group that catalyzes a separation of two sister circular DNAs. Moreover, also provided is a method comprising introducing oriC into circular DNA by using a transposon.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: June 27, 2023
    Assignee: Moderna Enzymatics Co., Ltd.
    Inventors: Masayuki Su'etsugu, Seia Nara
  • Patent number: 11672792
    Abstract: There is provided topical pharmaceutical formulations comprising montelukast, or a pharmaceutical acceptable salt of solvate thereof, as well as combination products comprising (a) at least one mussel adhesive protein or a derivative thereof; and (b) montelukast, or a pharmaceutically-acceptable salt or solvate thereof. The formulations and combination products find particular utility in direct topical administration for the treatment of inflammation, of inflammatory disorders and/or of condition characterized by inflammation, including wounds, burns, psoriasis, acne and atopic dermatitis.
    Type: Grant
    Filed: July 4, 2018
    Date of Patent: June 13, 2023
    Assignee: ENLITISA (SHANGHAI) PHARMACEUTICAL CO., LTD
    Inventors: Bengt Ingemar Samuelsson, Ming Gu
  • Patent number: 11643432
    Abstract: A nucleoside derivative represented below, or a salt thereof. (In (1), R1 represents a hydrogen atom, a hydroxyl group or a protected group, and in (2), X represent a halogen atom. In (1) and (2), R2 and R4 each represent a hydrogen atom, a hydroxyl protecting, phosphate, or protected phosphate group, or —P(?O)nR5R6 (n is 0 or 1, R5 and R6 each representing a hydrogen atom, hydroxyl, protected hydroxyl, mercapto, protected mercapto, lower alkoxy, cyano lower alkoxy, amino or substituted amino group, when n is 1, R5 and R6 are not both hydrogen atoms), R3 represents NHR7 (R7 represents a hydrogen atom, alkyl, alkenyl or protecting group for an amino group), an azide, amidino or guanidino group, each having a linking group (when R7 is hydrogen atom, the linking group is an alkylene group), and B represents any of a purine-9-yl, 2-oxo-pyrimidin-1-yl, substituted purine-9-yl or substituted 2-oxo-pyrimidin-1-yl group).
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: May 9, 2023
    Assignee: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM
    Inventor: Yoshihito Ueno
  • Patent number: 11642368
    Abstract: Compositions, methods, systems, etc., are provided for modified and/or purified fucans and corresponding fucan-containing compositions that inhibit fibrous adhesions among other advantages. The purified/modified fucans and fucan compositions have a reduced level of non-fucan components or impurities such as those found in a starting fucan composition. Such reduced undesirable components or impurities include, for example, undesired components bound to the fucan and compounds in the composition that are not a part of or bound to the fucan.
    Type: Grant
    Filed: July 24, 2019
    Date of Patent: May 9, 2023
    Assignee: ARC Medical Inc.
    Inventors: Christopher Michael Kevin Springate, Ian Millet, Sailesh Haresh Daswani, Hesong Sun, Aileen Shao Ting Yang, Hoi Ting Wong
  • Patent number: 11629176
    Abstract: A method of obtaining cell derived vesicles comprising an active wild-type p53 is disclosed. The method comprising: (i) isolating cell derived vesicles from a biological sample comprising cells; and (ii) treating the cell derived vesicles with a DNA damaging agent, or the method comprising: (i) treating cells with a DNA damaging agent; and (ii) isolating cell derived vesicles from a biological sample comprising the cells. A proteinaceous preparation comprising cell derived vesicles and a pharmaceutical composition comprising the proteinaceous preparation are also disclosed. Methods of treating a disease, disorder or condition associated with a mutant or a nonfunctional p53 protein and methods of inducing apoptosis of a target cell comprising a mutant or a nonfunctional p53 protein are also disclosed.
    Type: Grant
    Filed: March 21, 2018
    Date of Patent: April 18, 2023
    Assignee: Exoprother Medical Ltd.
    Inventors: Alexander Tendler, Lana Volokh
  • Patent number: 11618777
    Abstract: In order to provide a membrane protein production method which does not require the step of solubilizing a membrane protein and which allows the membrane protein having an excellent quality to be obtained with a high yield, a method in accordance with an embodiment of the present invention includes: a step (a) of preparing a reaction solution for cell-free protein synthesis, the reaction solution containing (i) a template nucleic acid which encodes the membrane protein, (ii) a lipid, and (iii) a detergent which is contained at a concentration equal to or higher than a critical micelle concentration; and a step (b) of synthesizing the membrane protein while the concentration of the detergent in the reaction solution is maintained at a concentration equal to or higher than a critical micelle concentration.
    Type: Grant
    Filed: July 29, 2016
    Date of Patent: April 4, 2023
    Inventor: Shigeyuki Yokoyama
  • Patent number: 11618770
    Abstract: The present invention provides a peptide that includes eight or more consecutive amino acid residues of amino acid sequence of one of Sequence ID Nos. 1 to 12 and that consists of eleven or less amino acid residues.
    Type: Grant
    Filed: February 19, 2020
    Date of Patent: April 4, 2023
    Assignee: NEC CORPORATION
    Inventors: Tomoya Miyakawa, Masaaki Oka, Shoichi Hazama, Koji Tamada, Keiko Udaka
  • Patent number: 11613732
    Abstract: A cell preservation medium, a cell recovery medium and a cell culture medium, and methods which employ the media, are provided.
    Type: Grant
    Filed: January 12, 2017
    Date of Patent: March 28, 2023
    Assignee: StemoniX Inc.
    Inventors: Fabian Zanella, Stephan Spangenberg, Wonjong Si, Ping Yeh, Robert John Petcavich
  • Patent number: 11603399
    Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of long-lived polynucleotides, primary transcripts and mmRNA molecules.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: March 14, 2023
    Assignee: ModernaTX, Inc.
    Inventors: Stephen G. Hoge, Eric Yi-Chun Huang, Tirtha Chakraborty, Sayda M. Elbashir
  • Patent number: 11571635
    Abstract: The present invention relates to a liquid chromatography system for the separation of bio-molecules in a fluid including at least two unit operations, wherein the first unit operation is a step of multi-column chromatography and the second unit operation is a step modifying said bio-molecules and/or the fluid, wherein the modification comprises feeding the fluid resulting from the last chromatography column of the first unit operation into a system comprising at least two containers, wherein each container has a volume and a moveable sidewall arranged to divide the volume into a first sub-volume and a second sub-volume, and each container comprises a first port connected to the first volume and a second port connected to the second sub-volume. The invention also relates to a virus inactivation device for a chromatography system according to the invention, which enables continuous or semi-continuous processing of biomolecules, as well as a method of using such a device.
    Type: Grant
    Filed: March 23, 2016
    Date of Patent: February 7, 2023
    Assignee: Cytiva Sweden AB
    Inventors: Bjorn Markus Olovsson, Anders Ljunglof, Karol Maciej Lacki
  • Patent number: 11555196
    Abstract: The present invention relates to a method for increasing the expression and/or promoting correct folding of a heterologous polypeptide of interest in a plant cell, comprising co-expressing the heterologous polypeptide of interest with a polypeptide encoding a mammalian chaperone protein. The invention also relates to plant cells and plants, which either transiently or stably, co-express the heterologous polypeptide of interest and the chaperone protein.
    Type: Grant
    Filed: June 1, 2018
    Date of Patent: January 17, 2023
    Assignee: UNIVERSITY OF CAPE TOWN
    Inventors: Ann Elizabeth Meyers, Edward Peter Rybicki, Emmanuel Aubrey Margolin
  • Patent number: 11535864
    Abstract: This invention comprises: compositions comprising a derivative, plasmids, a reagent kit and methods of making these compositions a derivative, vaccine- and non-vaccine-compositions of above for causing death of cancer cells that form part of a tunoour and virus infected Denguue, Measles and other diseased cells; the derivative comprising replicating as well as non-replicating dervivaties of an attenuated negative stranded RNA virus belonging to family paramyxoviridae, including Measles Virus, comprising a single additional transcriptional unit carrying either only one or two or more non-viral genes, and the non-replicating derivatives being free from contaminating replicating Measles Virus (b) a Measles Virus packaging cell line for making above compositions, expressing the M, F and H proteins of MV stably. And (c) a reagent kit for producing the Measles Virus derivatives describved above.
    Type: Grant
    Filed: January 4, 2016
    Date of Patent: December 27, 2022
    Inventor: Vishwas Dattatraya Joshi
  • Patent number: 11535876
    Abstract: The present disclosure relates to the field of genetic engineering, especially relates to a xylose-induced genetically engineered bacteria used for producing ectoine as well as a construction method and use thereof. The genetically engineered bacteria is constructed by heterologously expressing the ectABC gene cluster from Halomonas elongata on the E. coli chromosome, using the promoter of xylose transporter coding gene xylF to control the RNA polymerase from T7 bacteriophage, reconstructing a synthesis pathway of ectoine and constructing a plasmid-free system, and enhancing the expression of target genes by a strong promoter T7; the yield of ectoine reached 12-16 g/L after 20-28 h fermentation in shake flask, and reached 35-50 g/L after 24-40 h fermentation in a 5 L fermentor.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: December 27, 2022
    Assignee: Tianjin University of Science and Technology
    Inventors: Xixian Xie, Xuejiao Wu, Ning Chen, Fangqing Yan, Qian Ma, Jie Ma, Hongchao Zhang
  • Patent number: 11530428
    Abstract: The present invention provides for heterologous expression of polypeptides encoded by wild-type and condon-optimized variants of cbh1 and/or cbh2 from the fungal organisms Talaromyces emersonii (T. emersonii), Humicola grisea (H. grisea), Thermoascus aurantiacus (T. aurantiacus), and Trichoderma reesei (T. reesei) in host cells, such as the yeast Saccharomyces cerevisiae. The expression in such host cells of the corresponding genes, and variants and combinations thereof, result in improved specific activity of the expressed cellobiohydrolases. Thus, such genes and expression systems are useful for efficient and cost-effective consolidated bioprocessing systems.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: December 20, 2022
    Inventors: Riaan Den Haan, Emile Van Zyl, Danie LaGrange
  • Patent number: 11530430
    Abstract: Provided is a method capable of replicating or amplifying circular DNA, and particularly, long-chain circular DNA, in a cell-free system. Specifically, provided is a method for suppressing generation of a DNA multimer as a by-product, when circular DNA having a replication origin sequence (origin of chromosome (oriC)) is replicated or amplified by using the following enzyme groups: (1) a first enzyme group that catalyzes replication of circular DNA; (2) a second enzyme group that catalyzes an Okazaki fragment maturation and synthesizes two sister circular DNAs constituting a catenane; and (3) a third enzyme group that catalyzes a separation of two sister circular DNAs. Moreover, also provided is a method comprising introducing oriC into circular DNA by using a transposon.
    Type: Grant
    Filed: February 28, 2018
    Date of Patent: December 20, 2022
    Assignee: OriCiro Genomics, Inc.
    Inventors: Masayuki Su'etsugu, Seia Nara
  • Patent number: 11530260
    Abstract: A complex comprising a GDF15 polypeptide is described. Methods of treating individuals with a metabolism disorder, such as, glucose metabolism disorder and/or a body weight disorder, and compositions associated therewith, are provided.
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: December 20, 2022
    Assignee: NGM Biopharmaceuticals, Inc.
    Inventors: Wenyan Shen, Darrin Anthony Lindhout, Raj Haldankar, Hugo Matern
  • Patent number: 11530304
    Abstract: A biofabricated material comprising a network of crosslinked collagen fibrils produced from recombinant collagen that contains substantially no 3-hydroxyproline residues is disclosed. This material is composed of collagen which is also a major component of natural leather and is produced by a process of fibrillation of collagen molecules into fibrils, crosslinking the fibrils and lubricating the crosslinked fibrils. Unlike natural leathers, this biofabricated material exhibits non-anisotropic (not directionally dependent) physical properties, for example, a sheet of biofabricated material can have substantially the same elasticity or tensile strength when stretched or stressed in different directions. Unlike natural leather, it has a uniform texture that facilitates uniform uptake of dyes and coatings. Aesthetically, it produces a uniform and consistent grain for ease of manufacturability.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: December 20, 2022
    Assignee: MODERN MEADOW, INC.
    Inventors: Brendan Patrick Purcell, David Thomas Williamson, Lixin Dai, Darryl Miles Cassingham, Stephen M. Spinella, Katherine Amy Congdon
  • Patent number: 11526555
    Abstract: A system for determining user taste changes using a plurality of biological extraction data and artificial intelligence includes at least a computing device, wherein the computing device is designed and configured to receive, from a user, at least a first element of biological extraction data, calculate at least a first taste index of the user, wherein calculating further comprises training a first machine learning process as a function of training data correlating biological extraction data with taste indices, calculating the at least a first taste index as a function of the first machine learning process and the at least a first element of biological extraction data, generate a taste profile using the first taste index, and determine, using at least a second element of biological extraction data and a second machine learning process, at least a change in user taste profile.
    Type: Grant
    Filed: June 2, 2020
    Date of Patent: December 13, 2022
    Assignee: KPN INNOVATIONS, LLC.
    Inventor: Kenneth Neumann
  • Patent number: 11524073
    Abstract: The present invention discloses an application of a ?3 adrenergic receptor (ADRB3) as a marker for detecting a plurality of diseases, and an application of anti-human ADRB3 monoclonal antibody in diagnosing a disease and preparing a drug for treating the disease. The present invention finds through research that the ADRB3 is a key receptor in nerve-endocrine-immunoregulatory network, and an ADRB3-mediated signaling pathway regulates proliferation and differentiation of neutrophils, lymphocytes and tumor cells. Under normal circumstances, the ADRB3 maintains the non-specific immunocompetence and specific immunocompetence of an organism, and eliminates pathogenic microorganisms and aged organism tissues to play a role in protecting the organism and anti-aging. Under pathological conditions, excessive activation of the signaling pathway will cause systemic chronic inflammation, and destroy immune homeostasis.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: December 13, 2022
    Inventors: Meng Zheng, Shuguang Lin
  • Patent number: 11518781
    Abstract: A process for providing a mono-PEGylated protein composition is provided. The process is particularly suitable for providing mono-PEGylated erythropoietin composition. The process comprises subjecting a mixture comprising non-PEGylated, mono-PEGylated and oligo-PEGylated to a hydrophobic interaction chromatography process.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: December 6, 2022
    Assignee: Hoffmann-La Roche Inc.
    Inventor: Wolfgang Koehnlein
  • Patent number: 11519026
    Abstract: Sequencing adaptors and methods are provided for preparation of polynucleotides for sequencing. The sequencing adaptors contain a portion of a recognition sequence for a methyl-dependent endonuclease. Unwanted adaptor dimers that form during ligation of adaptors to target polynucleotides produce a complete restriction sequence and are cleaved by the endonuclease, followed by exonuclease digestion, thereby removing the dimers.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: December 6, 2022
    Assignee: Roche Sequencing Solutions, inc.
    Inventors: Arkadiusz Bibillo, Randall W. Davis
  • Patent number: 11512336
    Abstract: Described herein is a method for producing a transgenic cell product wherein the gene of interest is operably linked to an inducible promoter other than AOX1. Production of the transgenic cell product is activated when the host cell is grown on a non-repressing carbon source for de-repressing the inducible promoter and an amount of an inducer compound selected from the group consisting of: formaldehyde; S-formylglutathione; S-hydroxymethyl glutathione; formic acid; an alkali metal salt of formic acid; and an alkaline earth metal salt of formic acid; sufficient to induce the inducible promoter is added to the host cell culture.
    Type: Grant
    Filed: September 17, 2021
    Date of Patent: November 29, 2022
    Assignee: BioBoost Synbio Consulting Inc.
    Inventors: Oleg Tyurin, Mingyang Sun
  • Patent number: 11510911
    Abstract: The present invention relates to a method for predicting susceptibility to sorafenib treatment by using an SULF2 gene, and a composition for treatment of sorafenib-resistant cancer using the SULF2 expression inhibition. The method for predicting susceptibility to sorafenib treatment by using the SULF2 gene according to the present invention can enable achievement of an optimal therapeutic effect by administering a drug suitable for cancer patients, and the composition for treatment of sorafenib-resistant cancer using the SULF2 inhibition has a very excellent anticancer treatment effect.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: November 29, 2022
    Assignee: AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Hyun Goo Woo, Sarah Yoon, Eun-Ju Lee
  • Patent number: 11513126
    Abstract: Kits and methods of using the kits for analyzing macromolecules, including peptides, polypeptides, and proteins, employing nucleic acid encoding are disclosed. The sample analysis kits employ nucleic acid encoding and/or nucleic acid recording of a molecular interaction and/or reaction, such as recognition events (e.g., between an antigen and an antibody, between a modified terminal amino acid residue, or between a small molecule or peptide therapeutic and a target, etc.). Additional barcoding reagents, such as those for cycle-specific barcoding (e.g., “clocking”), compartment barcoding, combinatorial barcoding, spatial barcoding, or any combination thereof, may be included in the kits. The sample may comprise macromolecules, including peptides, polypeptides, and proteins, and the recording may generate molecular interaction and/or reaction information, and/or polypeptide sequence information.
    Type: Grant
    Filed: October 31, 2018
    Date of Patent: November 29, 2022
    Assignee: Encodia, Inc.
    Inventors: Mark S. Chee, John M. Beierle, Norihito Muranaka, Kevin L. Gunderson, Michael Phillip Weiner, Lei Shi, Robert C. James, Luca Monfregola
  • Patent number: 11492651
    Abstract: Methods and compositions for making bacteriocins are described in some embodiments herein. In some embodiments, pro-polypeptide comprising the bacteriocins in the desired ratios in cis, and separated by cleavage sited can be produced by a microbial cell comprising a nucleic acid encoding the pro-polypeptide. In some embodiments microfluidic devices and methods for making specified mixtures of antimicrobial peptides and/or bacteriocins are described.
    Type: Grant
    Filed: August 30, 2018
    Date of Patent: November 8, 2022
    Assignee: Syngulon SA
    Inventor: Philippe Gabant
  • Patent number: 11478553
    Abstract: Provided herein is an applicable bio-conjugation process for preparing antibody-drug conjugates (ADCs) with improved homogeneity. As compared with conventional conjugation process, the homogeneity of antibody-drug conjugate (ADC) products generated from the bio-conjugation process can be dramatically improved. Specifically, in the ADCs prepared by the process disclosed herein, the content of D0+D8 is less than 10 wt % and the content of D6 is less than 10 wt %. Moreover, the content of D4 is generally more than 65 wt %, for example, more than 70 wt %, and more than 77 wt %, while the content of D4 is normally less than 40 wt % in the ADCs prepared by conventional conjugation processes.
    Type: Grant
    Filed: February 14, 2020
    Date of Patent: October 25, 2022
    Assignee: WuXi Biologies Ireland Limited
    Inventors: Ao Ji, Chuchu Sun, Wenxu He
  • Patent number: 11479589
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 11, 2022
    Date of Patent: October 25, 2022
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Colette Song, Oliver Schoor, Jens Fritsche, Toni Weinschenk, Harpreet Singh
  • Patent number: 11479591
    Abstract: Described herein are modified fibroblast growth factor (FGF) polypeptides, pharmaceutical compositions and medicaments that include such modified FGF polypeptides, and methods of using such modified FGF polypeptides to treat or prevent conditions that benefit from administration of FGFs.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: October 25, 2022
    Assignee: TREFOIL THERAPEUTICS, INC.
    Inventors: David Eveleth, Jennifer Jenkins-Eveleth, Amuthakannan Subramaniam, Ralph Bradshaw
  • Patent number: 11472876
    Abstract: A non-naturally occurring polypeptide or isolated polypeptide having a ratio of at least 1.3 of an activity in an assay at a first pH in the presence of at least one species having a molecular weight of less than 900 a.m.u. and a pKa up to 4 pH units away from said first pH, to an activity in an assay at a second pH in the presence of the same at least one species. The species has a pKa between said first pH and said second pH and can be a small molecule. Also disclosed are pharmaceutical formulations including the polypeptide and uses thereof. Methods of producing conditionally active polypeptides are also disclosed.
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 18, 2022
    Assignee: BioAtla, Inc.
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 11471788
    Abstract: An ion exchange resin bag 5 includes a bag body 51 and a reinforcing body 52. The bag body 51 has a bottom surface portion 511 that is provided at an end portion opposite to an end portion where an opening is provided and forms a bottom surface of the bag body, and a side surface portion 512 that is connected to the bottom surface portion 511 and forms a side surface of the bag body 51. The reinforcing body 52 has a first reinforcing portion 521 that is fixed to a boundary portion of the bottom surface portion 511 and the side surface portion 512, and a second reinforcing portion 522 that is connected to the first reinforcing portion 521 and fixed to at least a part of the side surface portion 512 and extends from the first reinforcing portion 521 toward the opening.
    Type: Grant
    Filed: June 27, 2019
    Date of Patent: October 18, 2022
    Assignee: SUN MAINTENANCE KOKI CO., LTD.
    Inventor: Hiroshi Fukai
  • Patent number: 11467162
    Abstract: The present invention relates to a method for detecting fucosylated alpha1-acid glycoprotein (AGP) in a sample, comprising the steps providing a monovalent fucose-binding peptide having at least 80% identity, such as 85, 90, 95, 99 or 100% identity, to a peptide having an amino acid according to SEQ ID NO: 1, immobilised on a solid phase; bringing the sample into contact with the immobilised fucose-binding peptide; and detecting any fucosylated AGP bound to said fucose-binding peptide. The invention further relates to a method for assessing a risk that a human individual suffers from hepatocellular carcinoma, and to a kit of parts and antibodies useful in the methods according to the invention, and to a peptide useful as an immunizing antigen in production of such antibodies.
    Type: Grant
    Filed: May 8, 2017
    Date of Patent: October 11, 2022
    Assignee: Glycobond AB
    Inventor: Peter Påhlsson